Henry Meds tirzepatide review
$5,388 a year, all in. That is $3,888 more than the cheapest option. Sublingual and oral formats.
Updated 2026-09-18 · every price checked by hand
How we make money: one company on this page — Coreage Rx — pays us a commission when a reader signs up through our link. It buys them nothing else: not a better score, not a higher place in the table, not the removal of a single criticism. Our scoring method and full disclosure are both public.
Henry Meds charges no membership fee, then prices injectable tirzepatide at $449 a month — about $5,388 a year, the dearest compounded programme in our table.
The first month is $399 and renewals are $449. The company advertises that pricing "starts at $179 a month", which is true of its sublingual tier and not of the weekly injection most readers are picturing. Those are different products at different prices.
The yearly bill
| Henry Meds · tirzepatide | |
|---|---|
| Advertised from | $399/mo |
| Membership on top | None |
| What you actually pay | $449/mo |
| Over twelve months | $5,388 |
| Versus the cheapest option | +$3,888 a year |
| Cheapest-first position | 18 of 18 |
No separate membership, but the recurring injection price is the highest in this comparison.
Where the money goes
The absence of a membership is genuinely good practice, and it is worth saying that Henry is not hiding anything — the prices are published. It simply charges more for the medication than anyone else here. Multi-month blocks do bring it down: three months of oral tirzepatide is $1,047, or $891 paid up front.
Compounded GLP-1 provider with a strong oral and sublingual line alongside weekly injections, sold in monthly and prepaid multi-month blocks.
What the same money buys elsewhere
Coreage Rx month-to-month saves about $3,000 a year. Zealthy saves roughly $2,796. MEDVi and Willow at $399 a month save about $600. Almost every alternative is cheaper for the weekly injection.
| Programme | Per month | Per year | Extra vs cheapest |
|---|---|---|---|
| Coreage Rx Cheapest no membership fee | $199 | $2,388 | +$888 |
| Trimi no membership fee | $125 | $1,500 | — |
| Ozari Health no membership fee | $125 | $1,500 | — |
| Fifty 410 no membership fee | $133 | $1,596 | +$96 |
| PlexusDx no membership fee | $189 | $2,268 | +$768 |
| Ivím Health no membership fee | $199 | $2,388 | +$888 |
Is the extra worth it?
One scenario justifies it: you will not inject. Henry has the deepest oral and sublingual range here, and if a tablet or a sublingual drop is the difference between taking the medication and not taking it, the premium is beside the point.
What we checked
- Injectable tirzepatide listed at $399 for the first month and $449/month recurring.
- Oral tirzepatide tablets listed at $299 first month, $349/month recurring.
- Compounded semaglutide injection around $297/month; sublingual around $249/month with a $179/month tier.
- Three-month oral tirzepatide supply $1,047, or $891 paid in full.
- Three-month oral semaglutide supply $747, or $537 paid in full.
- Advertising states pricing "starts at $179/month", which corresponds to the lowest sublingual tier.
Verified 2026-09-18. Prices in this market move, so treat anything older than a month as a starting point rather than a quote.
The good
- No membership fee layered on top of medication.
- Real choice of sublingual, oral tablet and injection.
- Discounts for paying a multi-month block up front.
The bad
- Recurring injectable tirzepatide at $449/month is the most expensive compounded option here.
- The "$179" and "$297" figures describe different products, which readers routinely conflate.
- Month one and month two prices differ by $50.
Watch for this at checkout. The advertised "starts at $179" is the sublingual tier. Weekly injectable tirzepatide renews at $449/month.
Verdict
Buy the oral or sublingual products here. For the weekly injection you are paying roughly double the cheapest option for the same class of medication.
Full workings for every programme are in the cheapest tirzepatide programmes, and our scoring is explained on how we rate.